3 227

Cited 24 times in

Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression

Authors
 Jae Hoon Moon  ;  Saet Byol Kang  ;  Bong Soo Cha  ;  Hyun Chul Lee  ;  Chul Woo Ahn  ;  Eun Seok Kang  ;  Byung Wan Lee  ;  Jong Suk Park 
Citation
 Metabolism: Clinical and Experimental, Vol.60(7) : 930-940, 2011 
Journal Title
 Metabolism: Clinical and Experimental 
ISSN
 0026-0495 
Issue Date
2011
Abstract
Low-density lipoprotein receptor-related protein 1 (LRP1) binds to apolipoprotein E and serves as a receptor for remnant lipoproteins in the liver, thus playing an important role in clearing these atherogenic particles. In this study, we investigated the effect of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, on hepatic LRP1 expression. We used HepG2 and Hep3B cells for in vitro study, and Otsuka Long-Evans Tokushima fatty and Sprague-Dawley rats for in vivo study. We used relatively high pharmacologic dose of atorvastatin in this study (in vitro, 0.5 μmol/L in culture media, for 48 hours; in vivo, 20 mg/[kg d], for 6 weeks). Atorvastatin increased LRP1 and low-density lipoprotein (LDL) receptor expression in HepG2 and Hep3B cells and induced hepatic LRP1 and LDL receptor expression in chow diet-fed Sprague-Dawley rats and high-fat diet-fed Otsuka Long-Evans Tokushima fatty rats. Atorvastatin decreased intracellular sterol level and increased the amount of the nuclear form of sterol response element-binding protein-2 (SREBP-2) in both HepG2 and Hep3B cells as well as in two animal models. Treatment of HepG2 cells with LDL increased intracellular sterol level and reduced LRP1, LDL receptor, and SREBP-2. When SREBP-2 in HepG2 cells was knocked down by small interfering RNA, the induction of LRP1 expression by atorvastatin did not take place. In conclusion, up-regulation of hepatic LRP1 might be a novel mechanism by which statin treatment decreases remnant lipoproteins. In addition, SREBP-2 acts as a mediator of atorvastatin-induced up-regulation of hepatic LRP1. Future studies using standard doses of atorvastatin in humans are needed to elucidate clinical relevance of these findings.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/93744
DOI
10.1016/j.metabol.2010.08.013
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Medical Research Center (임상의학연구센터)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
강샛별(Kang, Saet Byol) ; 강은석(Kang, Eun Seok) ; 문재훈(Moon, Jae Hoon) ; 박종숙(Park, Jong Suk) ; 안철우(Ahn, Chul Woo) ; 이병완(Lee, Byung Wan) ; 이현철(Lee, Hyun Chul) ; 차봉수(Cha, Bong Soo)
사서에게 알리기
  feedback
Full Text
http://www.sciencedirect.com/science/article/pii/S002604951000301X
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse